June Carl H
Abramson Family Cancer Research Institute and Department of Pathology and Laboratory Medicine, University of Pennsylvania, 421 Curie Boulevard, Philadelphia, PA 19104, USA.
J Clin Invest. 2007 May;117(5):1204-12. doi: 10.1172/JCI31446.
The transfusion of T cells, also called adoptive T cell therapy, is an effective treatment for viral infections and has induced regression of cancer in early-stage clinical trials. However, recent advances in cellular immunology and tumor biology are guiding new approaches to adoptive T cell therapy. For example, use of engineered T cells is being tested as a strategy to improve the functions of effector and memory T cells, and manipulation of the host to overcome immunotoxic effects in the tumor microenvironment has led to promising results in early-stage clinical trials. Challenges that face the field and must be addressed before adoptive T cell therapy can be translated into routine clinical practice are discussed.
T细胞输注，也称为过继性T细胞疗法，是治疗病毒感染的一种有效方法，并且在早期临床试验中已使癌症出现消退。然而，细胞免疫学和肿瘤生物学的最新进展正在引领过继性T细胞疗法的新方法。例如，工程化T细胞的使用正在作为一种改善效应T细胞和记忆T细胞功能的策略进行测试，并且对宿主进行调控以克服肿瘤微环境中的免疫毒性作用在早期临床试验中已取得了有前景的结果。本文讨论了该领域面临的挑战，这些挑战在过继性T细胞疗法能够转化为常规临床实践之前必须得到解决。
